Financial Performance Overview
Syngene International Limited reported mixed financial results for FY 2025-26, with consolidated revenue growing 2.6% to ₹37,387 million but net profit declining 36.2% to ₹3,167 million. The profit decline was primarily driven by exceptional items totaling ₹766 million, including ₹462 million for labor code implementation impacts and ₹304 million in termination benefits. Operating EBITDA margin stood at 25%, while profit after tax before exceptional items was ₹3,799 million.
Operational and Strategic Developments
The company made significant strategic progress with capacity expansion in peptides and antibody-drug conjugates, commissioning of Unit 3 biologics manufacturing facility, and acquisition of a US biologics site from Emergent Manufacturing Operations Baltimore, LLC for approximately USD 50 million. Digital transformation initiatives advanced with AI-enabled platform (Syn.AI) implementation, SARchitect™ proprietary 3D visualization, and end-to-end digitization of BA/BE trials.
Corporate Governance and Leadership Changes
Key management changes included the appointment of Siddharth Mittal as Managing Director & CEO effective July 1, 2026, for a five-year term with total compensation of ₹250 million per annum, replacing Peter Bains who stepped down on June 30, 2026. Kiran Mazumdar-Shaw transitioned to Executive Chairperson from April 1, 2026. The Board recommended a final dividend of ₹1.25 per equity share, subject to shareholder approval at the 33rd AGM scheduled for July 29, 2026.
ESG Performance and Sustainability
Syngene demonstrated strong ESG performance with 92% renewable energy usage, 97% waste recycling, and recognition as India's Most Sustainable Company by TIME magazine. The company published its assured BRSR Core Report covering nine sustainability indicators verified by Adwin Advisory, showing a 45% reduction in Scope 1 & 2 emissions and 19.9% of wages paid to females. Safety performance metrics showed TRCR at 0.12 and LTIIR at 0.03.
Financial Position and Capital Structure
The company maintained a strong financial position with net cash of ₹18,003 million and total equity of ₹48,391 million. Borrowings were significantly reduced to ₹94 million from ₹1,196 million in FY25. Capital expenditure continued with ₹3,440 million in property, plant & equipment additions and ₹10,402 million in capital work-in-progress. The debt-equity ratio remained low at approximately 0.002.
Regulatory Compliance and Forward Outlook
All regulatory requirements under SEBI Listing Regulations and Companies Act were complied with, including comprehensive disclosures in the annual report and BRSR Core report. The near-term environment is expected to remain measured, with the impact of the biologics program continuing into the first half of FY27, but healthy pipeline and sustained customer engagement provide confidence for growth and operating leverage over time.